Pfizer's (NYSE: PFE) management team is confident in its 2025 opportunities. Where to invest $1,000 right now? Our analyst ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

Pfizer Inc. closed 25.65% short of its 52-week high of $31.54, which the company achieved on July 30th.

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

the stock appears undervalued based on its Fair Value estimates, suggesting potential upside for investors. This comprehensive analysis examines Pfizer’s current position, recent performance ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

Value investors rely on traditional forms of analysis on key ... now is Pfizer (PFE). PFE is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock is trading with P/E ratio ...

Our detailed analysis of Pfizer’s upside post-inflation shock captures trends in the company’s stock during the turbulent market conditions seen over 2022. It compares these trends to the ...